CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 412 target
Drug / intervention
Savolitinib +1 moredrug
Likely dose
Savolitinib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05009836
NCT05009836Phase 3ActiveOn Track
CompareCT.gov

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC

Hutchison Medipharma Limited·interventional·Posted Aug 18, 2021·Updated Jun 10, 2026

In Brief

A Phase 3 clinical trial evaluating Savolitinib and Placebo for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 412 participants across 1 site.

Detailed Summary

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 3Active
2022202320242025202620272028
First PostedAug 18, 2021
Enrollment StartSep 6, 2021
Primary CompletionMay 30, 2028
TodayJul 1, 2026
Enrollment to primary: 6.7 yearsPosted 4.9 years agoPrimary completion in 1.9 years

Arms & Interventions

Savolitinibexperimental

Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally

Drug: Savolitinib
placeboplacebo_comparator

Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally

Drug: Placebo

Interventions

Savolitinibdrug

Subjects will receive Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally, 21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Placebodrug

Subjects will receive Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally, 21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.